Society for Industrial Microbiology & Biotechnology

The Challenge of Scale-up
Prof. Behnam Taidi¹, Dr. Thomas Chastang¹ and Dr. Anthony Bresin², (1)LGPM (Laboratory of Chemical Engineering and Materials), Centralesupelec Paris, Châtenay-Malabry, France, (2)Chief Scientific Officer, ARD, Pomacle, France

Harnessing the Predictive Power of Microtiter Plate Models for Multiple Products in Fermentation Scale Up
Elizabeth Carroll Olsson, Screening and Analytics, Amyris, Inc, Emeryville, CA

Break

ambr250™: advanced tools for automated process development, optimisation and scale-up in both microbial and cell cultures for biotherapeutics
Mwai Ngibuini, Sartorius Stedim, Royston, United Kingdom

ROBUST technology for antibiotics-free contamination resistance
Joe Shaw¹, Maureen Hamilton¹, Elena Brevnova¹, Andrew Consiglio¹, Kyle MacEwen¹, Johannes van Dijken², Colin South¹, Vineet Rajgarhia³ and Greg Stephanopoulos⁴, (1)Novogy Inc., Cambridge, MA, (2)Professor Emeritus, Delft University of Technology, Leidschendam, Netherlands, (3)Total New Energies USA, Emeryville, CA, (4)Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA

Bio-process scaling and optimization – from bench to piloting at the DOE Berkeley Lab ABPDU
Dr. Todd Pray, Advanced Biofuels (and Bioproducts) Process Demonstration Unit (AB-PDU), Lawrence Berkeley National Laboratory, Emeryville, CA

Exometabolome analysis reveals hypoxia at the up-scaling of a Saccharomyces cerevisiae high-cell density fed-batch biopharmaceutical process
Juan Aon¹, Zhibiao Fu¹, Ed Appelbaum¹, Julie Leighton², Jianxin Sun², Prem Patel¹ and Thomas Verderame³, (1)Microbial and Cell Culture Development, GlaxoSmithKline, King of Prussia, PA, (2)Microbial and Cell Culture, GlaxoSmithKline, King of Prussia, PA, (3)Production/Manufacturing Operations, GlaxoSmithKline, King of Prussia, PA